Janssen Biotech Inc.

03/22/2024 | Press release | Distributed by Public on 03/22/2024 16:24

U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)